Home | Print This Page | Site Map
Search
blue bar
Pandemic Planning Toolkit A resource to assist your organization in preparing for pandemic influenza

TAMIFLU® (oseltamivir phosphate) has been studied only in strains of influenza that were circulating at the time. The magnitude of effect of TAMIFLU in treating and preventing novel strains of influenza, such as those that may be involved in a pandemic, cannot be predicted.

How would a pandemic impact the US economy?
A pandemic could deliver a "shock" to the economy, with immediate demand- and supply-side effects, as well as longer-term supply-side effects.17
 
The general slowdown in economic activity would reduce gross domestic product (GDP). Business confidence would be dented, the supply of labor would be restricted, supply chains would be strained as transportation systems were disrupted, and arrears and default rates on consumer and business debt would probably rise. It seems likely that the stock market would initially fall and rebound later.17
 
Estimates of the economic impact vary widely. A pandemic could cause a serious recession in the US economy, with immediate costs ranging from $500 billion to $675 billion. The following is a sampling of predictions from financial leaders:18
  • WBB Securities LLC predicted a pandemic could cause a one-year economic loss of $488 billion and a permanent economic loss of $1.4 trillion to the US economy
  • The Congressional Budget Office said a pandemic could deal a $675 billion hit to the US economy
  • The World Bank has predicted a pandemic could cost the global economy $800 billion a year
Learn how the US government is protecting the country in case of a pandemic.



 
FOOTNOTE
17. Congressional Budget Office. A potential influenza pandemic: possible macroeconomic effects and policy issues. December 2005. Available at: http://www.cbo.gov/ftpdocs/69xx/doc6946/12-08-BirdFlu.pdf. Accessed April 13, 2006. 18. Death toll from bird flu hits 70 as Thai boy dies. The New Zealand Herald. October 12, 2005. Available at: http://www.nzherald.co.nz/section/print.cfm. Accessed April 13, 2006
Indications

TAMIFLU is indicated for the treatment of uncomplicated influenza caused by viruses types A and B in patients 1 year and older who have been symptomatic for no more than 2 days.

TAMIFLU is also indicated for the prophylaxis of influenza in patients 1 year and older.

TAMIFLU is not a substitute for early and annual vaccination as recommended by the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP).

Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use TAMIFLU.

Safety Information

There is no evidence for efficacy against any illness caused by agents other than influenza types A and B.

Treatment efficacy in subjects with chronic cardiac and/or respiratory disease has not been established. No difference in the incidence of complications was observed between the treatment and placebo groups in this population.

No information is available regarding treatment of influenza in patients at imminent risk of requiring hospitalization.

Efficacy of TAMIFLU has not been established in immunocompromised patients.

Safety and efficacy of repeated treatment or prophylaxis courses have not been studied.

Influenza can be associated with a variety of neurologic and behavioral symptoms, which can include events such as hallucinations, delirium and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease. There have been postmarketing reports (mostly from Japan) of delirium and abnormal behavior leading to injury, and in some cases resulting in fatal outcomes, in patients with influenza who were receiving TAMIFLU. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made but they appear to be uncommon based on TAMIFLU usage data. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. The contribution of TAMIFLU to these events has not been established. Patients with influenza should be closely monitored for signs of abnormal behavior. If neuropsychiatric symptoms occur, the risks and benefits of continuing treatment should be evaluated for each patient.

In postmarketing experience, rare cases of anaphylaxis and serious skin reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, have been reported with TAMIFLU.

The most common adverse events reported >1% of patients treated with TAMIFLU and more commonly than in patients treated with placebo are:

  • Treatment of adult and pediatric patients - nausea, vomiting.
  • Prophylaxis of adult and pediatric patients - nausea, vomiting, abdominal pain.

Vaccination is considered the first line of defense against influenza.

Please see TAMIFLU full Prescribing Information for additional safety information.

 

Roche